Extended Dosing Improves Safety of IkT-148009, Animal Studies Show

Extended Dosing Improves Safety of IkT-148009, Animal Studies Show

309096

Extended Dosing Improves Safety of IkT-148009, Animal Studies Show

The safety profile of IkT-148009, an investigational oral medication for Parkinson’s disease, improved the longer the drug was dosed, demonstrating target selectivity, according to interim three-month animal data. The ongoing toxicology studies, conducted by the therapy’s developer, Inhibikase Therapeutics, were designed to meet regulatory requirements for regular dosing in humans, including daily administration in rats for six months and non-human primates for nine months. Following a review of these results by the U.S. Food and…

You must be logged in to read/download the full post.